Text Size
1849 studies found for:    Ovarian Cancer: Clinical Trials

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Completed Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy
Condition: Ovarian Neoplasms
Intervention: Drug: doxorubicin hydrochloride
22 Terminated A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Conditions: Carcinoma;   Ovarian Cancer;   Ovarian Diseases;   Ovarian Neoplasms
Interventions: Biological: AGS-8M4;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: gemcitabine;   Drug: carboplatin
23 Recruiting 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Conditions: Ovarian Neoplasms;   Ovarian Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Cancer
Interventions: Drug: [18F]-CP18;   Procedure: PET/ CT
24 Completed A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
Conditions: Carcinoma;   Ovarian Cancer;   Ovarian Diseases;   Ovarian Neoplasms
Intervention: Biological: AGS-8M4
25 Completed
Has Results 		Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
Conditions: Neoplasms;   Cancer of the Ovary
Intervention: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
26 Active, not recruiting Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
Condition: Epithelial Ovarian Cancer
Intervention: Biological: MUC1 Dendritic Cell Vaccine (Cvac)
27 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
28 Recruiting MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Conditions: Ovarian Carcinoma;   Fallopian Tube Cancer;   Peritoneal Cancer;   Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel;   Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
29 Terminated Clinical Trial for Ovarian Cancer (OvaRex®)
Condition: Ovarian Cancer
Intervention: Drug: oregovomab
30 Active, not recruiting
Has Results 		Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281
31 Completed Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Procedure: Tenckhoff Catheter placement;   Drug: Ad5-delta24RGD
32 Completed Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Condition: Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Drug: M200 (Volociximab);   Drug: Liposomal Doxorubicin
33 Terminated
Has Results 		Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo
34 Recruiting Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
Condition: Ovarian Cancer
Interventions: Drug: stealth liposomal doxorubicin;   Drug: carboplatin;   Drug: paclitaxel;   Drug: Topotecan;   Drug: Gemcitabine
35 Active, not recruiting An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: cediranib
36 Recruiting Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: VS-6063;   Drug: Paclitaxel
37 Completed Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Primary Peritoneal Carcinoma;   Epithelial Ovarian Carcinoma;   Neoplasms, Ovarian;   Fallopian Tube Cancer
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
38 Completed A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention: Drug: LY573636
39 Recruiting Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: FANG;   Drug: standard of care observational follow-up
40 Recruiting A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Conditions: Solid Tumors;   Ovarian Cancer
Interventions: Drug: OSI-906;   Drug: Paclitaxel
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years